Your session is about to expire
← Back to Search
BI 905711 + Chemotherapy for Gastrointestinal Cancer
Study Summary
This trial is for adults with advanced colorectal or pancreatic cancer. The first part is to find the highest tolerable dose of BI 905711, and the second part is to see if BI 905711 makes tumours shrink. BI 905711 is given every 2 weeks as an infusion, and participants can stay in the study for as long as the treatment is effective and tolerable.
- Metastatic Gastrointestinal Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 45 Patients • NCT02036424Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken any non-experimental drugs, like bevacizumab, ramucirumab, aflibercept, cetuximab, or panitumumab, within the past 14 days.You have not taken any experimental drugs or immune checkpoint inhibitors in the past 28 days.You have a long-term condition called chronic pancreatitis.You have a severe gastrointestinal condition diagnosed by a doctor, such as an autoimmune disease affecting the GI tract or unexplained persistent diarrhea with a severity grade of 2 or higher.
Frequently Asked Questions
Is it possible to sign up for this experiment at this time?
"Yes, the clinical trial is still recruiting patients. The original posting was on November 24th, 2021 and the most recent update was on November 17th, 2022."
What other scientific studies have been performed that focus on BI 905711?
"As of now, there are 834 ongoing trials for BI 905711 with the majority being in Phase 3. Out of these 226 trials, most are based in Shanghai. However, there are a total of 39489 locations running studies related to BI 905711."
What is the most common reason why BI 905711 is given to patients?
"BI 905711 is an effective treatment against rectal carcinoma, colorectal carcinoma, and sarcoma."
How many study subjects are participating in this research project?
"The listing on clinicaltrials.gov says that this trial is open and looking for 100 participants at 1 site. The study was posted on November 24th, 2021 and updated on November 17th, 2022."
What is the official stance of the FDA on BI 905711?
"BI 905711 falls into the Phase 1 category, which means that there is only preliminary data to support its safety and efficacy. Our team at Power estimates it to be a 1 on our scale."
Share this study with friends
Copy Link
Messenger